Skip to main content
. Author manuscript; available in PMC: 2018 May 9.
Published in final edited form as: J Virol Methods. 2018 Feb 23;255:84–90. doi: 10.1016/j.jviromet.2018.02.018

Table 1.

Spearman correlation between rel[Ab] obtained from the ADI and FANG ELISAs by evaluation time.

Time of evaluation rChAd3 EBO Z rVSVΔG-ZEBOV GP Placebo
Baseline 0.213 0.269 0.274
1 mo post-vaccination 0.584 0.674 0.303
Total no. tested 487 484 491

ChAd3 EBO Z, chimpanzee adenovirus type 3 expressing Ebola virus glycoprotein Yambuku variant; rVSVΔG-ZEBOV, recombinant vesicular stomatitis virus with substitution of gene for Ebola virus glycoprotein for the VSV G glycoprotein.